<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anticancer drug-related nephrotoxicity</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anticancer drug-related nephrotoxicity</h1>
<div class="graphic"><div class="figure"><div class="ttl">Anticancer drug-related nephrotoxicity</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Clinical renal syndrome</td> <td class="subtitle1">Renal histopathology</td> <td class="subtitle1">Prevention*</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Cytotoxic drugs</td> </tr> <tr class="divider_bottom"> <td class="indent1">Cyclophosphamide</td> <td> <ul> <li>Hyponatremia (SIADH) </li> <li>Hemorrhagic cystitis </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul> <li>Intravenous fluids </li> <li>Mesna </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Gemcitabine</td> <td> <ul> <li>AKI </li> <li>Hematuria </li> <li>Hypertension </li> <li>Proteinuria </li> </ul> </td> <td> <ul> <li>Thrombotic microangiopathy </li> </ul> </td> <td> <ul> <li>Not available </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Ifosfamide</td> <td> <ul> <li>AKI </li> <li>NDI </li> <li>Proximal tubulopathy (Fanconi syndrome) </li> </ul> </td> <td> <ul> <li>Acute tubular injury </li> </ul> </td> <td> <ul> <li>Dose adjustment </li> <li>Intravenous fluids </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Methotrexate</td> <td> <ul> <li>AKI </li> </ul> </td> <td> <ul> <li>Acute tubular injury </li> <li>Crystalline nephropathy </li> </ul> </td> <td> <ul> <li>Intravenous fluids </li> <li>Urinary alkalinization </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Mitomycin C</td> <td> <ul> <li>AKI </li> <li>Hematuria </li> <li>Hypertension </li> <li>Proteinuria </li> </ul> </td> <td> <ul> <li>Thrombotic microangiopathy </li> </ul> </td> <td> <ul> <li>Not available </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Nitrosoureas</td> <td> <ul> <li>Chronic kidney disease </li> </ul> </td> <td> <ul> <li>Chronic interstitial nephritis </li> </ul> </td> <td> <ul> <li>Intravenous fluids </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Pemetrexed</td> <td> <ul> <li>AKI </li> <li>NDI </li> <li>Proximal tubulopathy (Fanconi syndrome) </li> </ul> </td> <td> <ul> <li>Acute tubular injury </li> <li>Interstitial fibrosis </li> </ul> </td> <td> <ul> <li>Intravenous fluids </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Platinum agents (cisplatin, carboplatin, oxaliplatin)</td> <td> <ul> <li>AKI </li> <li>Hypomagnesemia </li> <li>NDI </li> <li>Proximal tubulopathy (Fanconi syndrome) </li> <li>Salt wasting </li> </ul> </td> <td> <ul> <li>Acute tubular injury </li> </ul> </td> <td> <ul> <li>Dose adjustment </li> <li>Intravenous fluids </li> <li>Intravenous magnesium </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Vinca alkaloids</td> <td> <ul> <li>Hyponatremia (SIADH) </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul> <li>Not available </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Targeted agents</td> </tr> <tr class="divider_bottom"> <td class="indent1">ALK inhibitors (crizotinib)</td> <td> <ul> <li>AKI </li> <li>Electrolyte disorders </li> <li>Renal microcysts </li> </ul> </td> <td> <ul> <li>Acute interstitial nephritis </li> <li>Acute tubular injury </li> </ul> </td> <td> <ul> <li>Not available </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Anti-VEGF agents (aflibercept, bevacizumab)</td> <td> <ul> <li>AKI </li> <li>Hypertension </li> <li>Proteinuria </li> </ul> </td> <td> <ul> <li>Thrombotic microangiopathy </li> </ul> </td> <td> <ul> <li>Not available </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">BRAF inhibitors (dabrafenib, vemurafenib)</td> <td> <ul> <li>AKI </li> <li>Electrolyte disorders </li> </ul> </td> <td> <ul> <li>Acute interstitial nephritis </li> <li>Acute tubular injury </li> </ul> </td> <td> <ul> <li>Not available </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">EGFR inhibitors (cetuximab, erlotinib, gefitinib, panitumumab)</td> <td> <ul> <li>Hypomagnesemia </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul> <li>Not available </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Imatinib</td> <td> <ul> <li>AKI </li> <li>Chronic kidney disease </li> </ul> </td> <td> <ul> <li>Acute tubular injury </li> </ul> </td> <td> <ul> <li>Not available </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Rituximab</td> <td> <ul> <li>AKI (tumor lysis syndrome) </li> </ul> </td> <td> <ul> <li>Acute tubular injury </li> <li>Crystalline (uric acid) nephropathy </li> </ul> </td> <td> <ul> <li>Hypouricemic agents (allopurinol, rasburicase) </li> <li>Intravenous fluids </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Tyrosine kinase inhibitors (axitinib, pazopanib, sorafenib, regorafenib, sunitinib)</td> <td> <ul> <li>AKI </li> <li>Hypertension </li> <li>Proteinuria </li> </ul> </td> <td> <ul> <li>Acute interstitial nephritis </li> <li>Acute tubular injury </li> <li>Focal segmental glomerulosclerosis </li> <li>Thrombotic microangiopathy </li> </ul> </td> <td> <ul> <li>Not available </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Immunotherapy agents</td> </tr> <tr class="divider_bottom"> <td class="indent1">Chimeric antigen receptor (CAR) T cells</td> <td> <ul> <li>Capillary leak syndrome with AKI </li> <li>Electrolyte disorders </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul> <li>Glucocorticoid prophylaxis </li> <li>Chemotherapy to reduce tumor burden </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">CTLA-4 inhibitors (ipilimumab, tremelimumab)</td> <td> <ul> <li>AKI </li> <li>Proteinuria </li> </ul> </td> <td> <ul> <li>Acute interstitial nephritis </li> <li>Lupus-like glomerulonephritis </li> <li>Minimal change disease </li> </ul> </td> <td> <ul> <li>Not available </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Interferons (alpha, beta, gamma)</td> <td> <ul> <li>AKI </li> <li>Nephrotic-range proteinuria </li> </ul> </td> <td> <ul> <li>Focal segmental glomerulosclerosis </li> <li>Thrombotic microangiopathy </li> </ul> </td> <td> <ul> <li>Not available </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Interleukin-2</td> <td> <ul> <li>AKI </li> <li>Capillary leak syndrome </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul> <li>Intravenous fluids </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">PD-1 inhibitors (nivolumab, pembrolizumab, cemiplimab)</td> <td> <ul> <li>AKI </li> <li>Proteinuria </li> </ul> </td> <td> <ul> <li>Acute interstitial nephritis </li> <li>Acute tubular injury </li> <li>IgA nephropathy </li> <li>Minimal change disease </li> <li>Focal segmental glomerulosclerosis </li> <li>C3 glomerulopathy </li> <li>Membranous glomerulonephritis </li> </ul> </td> <td> <ul> <li>Not available </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">PD-L1 inhibitors (atezolizumab, durvalumab, avelumab)</td> <td> <ul> <li>AKI </li> </ul> </td> <td> <ul> <li>Acute interstitial nephritis </li> </ul> </td> <td> <ul> <li>Not available </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Other drugs</td> </tr> <tr class="divider_bottom"> <td class="indent1">Deferasirox</td> <td> <ul> <li>AKI </li> </ul> </td> <td> <ul> <li>Acute interstitial nephritis </li> <li>Acute tubular injury </li> <li>Fanconi syndrome </li> </ul> </td> <td> <ul> <li>Not available </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Pamidronate</td> <td> <ul> <li>AKI </li> <li>Nephrotic syndrome </li> </ul> </td> <td> <ul> <li>Acute tubular injury </li> <li>Focal segmental glomerulosclerosis </li> </ul> </td> <td> <ul> <li>Dose adjustment </li> <li>Increase infusion time </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Sirolimus</td> <td> <ul> <li>AKI </li> <li>Proteinuria </li> </ul> </td> <td> <ul> <li>Focal segmental glomerulosclerosis </li> </ul> </td> <td> <ul id="_telerik_insertedList_id"> <li>Not available </li> </ul> </td> </tr> <tr> <td class="indent1">Zoledronate</td> <td> <ul> <li>AKI </li> <li>Nephrotic syndrome </li> </ul> </td> <td> <ul> <li>Acute tubular injury </li> <li>Focal segmental glomerulosclerosis (rare) </li> </ul> </td> <td> <ul> <li>Dose adjustment </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">SIADH: syndrome of inappropriate antidiuretic hormone; AKI: acute kidney injury; NDI: nephrogenic diabetes insipidus; ALK: anaplastic lymphoma kinase; VEGF: vascular endothelial growth factor; EGFR: epidermal growth factor receptor; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; PD-1: programmed cell death-1; PD-L1: programmed cell death-1 ligand-1.<br/>* In addition to minimizing exposure to other nephrotoxins.</div><div id="graphicVersion">Graphic 112219 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
